Navigating diagnostic shifts: A comparative review of the WHO 5th edition and ICC 2022 classifications of myeloid neoplasms.
1/5 보강
The near-simultaneous publication of the World Health Organization (WHO) 5th Edition classification of hematolymphoid tumors (WHO-HAEM5) and the International Consensus Classification (ICC) in 2022 re
APA
Koorse Germans S, Weinberg OK (2026). Navigating diagnostic shifts: A comparative review of the WHO 5th edition and ICC 2022 classifications of myeloid neoplasms.. Human pathology, 169, 106077. https://doi.org/10.1016/j.humpath.2026.106077
MLA
Koorse Germans S, et al.. "Navigating diagnostic shifts: A comparative review of the WHO 5th edition and ICC 2022 classifications of myeloid neoplasms.." Human pathology, vol. 169, 2026, pp. 106077.
PMID
41720165 ↗
Abstract 한글 요약
The near-simultaneous publication of the World Health Organization (WHO) 5th Edition classification of hematolymphoid tumors (WHO-HAEM5) and the International Consensus Classification (ICC) in 2022 represents a pivotal moment in the taxonomy of myeloid neoplasms. Both systems emphasize integration of morphology, cytogenetics, and molecular genetics, yet they diverge in several clinically meaningful areas, including blast thresholds for acute myeloid leukemia (AML), definition of the myelodysplastic syndrome (MDS)-AML interface, and categorization of TP53-mutated disease [TP53mut MN] [1-3]. These differences extend beyond nomenclature, influencing prognostic stratification, therapeutic decision-making, and eligibility for clinical trials [4-7]. Recent comparative cohort studies demonstrate substantial reclassification rates, particularly among MDS with excess blasts, AML with myelodysplasia-related features, and TP53-mutated neoplasms, with prognosis driven largely by underlying molecular features rather than blast percentage alone [8-11]. This review provides a comprehensive comparison of WHO-HAEM5 and ICC 2022, synthesizes emerging real-world outcome data, and discusses implications for diagnostic practice, harmonization efforts, and future refinement of myeloid neoplasm classification [12-14].
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.